Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
57 hedge funds and large institutions have $65.7M invested in Genocea Biosciences, Inc. in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 59 → 57 (-2)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
52% less capital invested
Capital invested by funds: $136M → $65.7M (-$69.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.59M |
| 2 |
Millennium Management
New York
|
+$668K |
| 3 |
Franklin Resources
San Mateo,
California
|
+$636K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$373K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$264K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.33M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.29M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.23M |
| 4 |
JP Morgan Chase
New York
|
-$983K |
| 5 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$924K |
GNCA Hedge Fund Activity: Q2 2016 in Review
57 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2016, worth a combined $65.7M — down 52% from $136M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of GNCA and 16 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 12 added.
The largest buyer was Sphera Funds Management, adding an estimated $1.59M. The largest seller was BlackRock Fund Advisors, cutting an estimated $2.33M.
- 57 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2016, down from 59 in Q1 2016.
- Funds reported $65.7M of Genocea Biosciences, Inc. stock for Q2 2016, down 52% quarter-over-quarter.
- 16 funds opened new Genocea Biosciences, Inc. positions in Q2 2016 and 18 closed out, a net change of -2 holders.
- The largest Genocea Biosciences, Inc. buyer in Q2 2016 was Sphera Funds Management, an estimated $1.59M added.
- The largest Genocea Biosciences, Inc. seller in Q2 2016 was BlackRock Fund Advisors, an estimated $2.33M sold.
Based on aggregated 13F filings for Q2 2016.